Bioject Establishes Strategic Alliance with MPI Research
News Jan 06, 2010
Bioject Medical Technologies Inc. has announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.
“Bioject and MPI Research share an innovative and entrepreneurial spirit that creates a synergy vital to our industry. It is a pleasure to collaborate with a company that has such highly-developed technological expertise and strategic vision.”
The strategic alliance creates a preferred partnership relationship which allows Bioject to gain access to a range of capabilities and resources needed for the company to explore our drug+device opportunities, including access to pharmacologic, analytical, safety and other preclinical testing resources available at MPI Research.
The strategic alliance offers MPI Research the opportunity to provide Bioject’s needle-free technology as an alternate delivery option to current drug/biologic manufacturers who may be interested in seeking a highly competitive and differentiable drug+device brand.
This alliance also increases the possibility that Bioject and MPI Research may be able to secure government sponsored grants or funding directed at improvements in drug+device or vaccine+device based treatments, which could also lead to potential new drug+device combinations.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE